GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Sophiris Bio Inc. (SPHS) [hlAlert]

Rating:
Buy SPHS
down 71.04 %

Sophiris Bio Inc. (SPHS) rated Buy with price target $10 by Maxim Group

Posted on: Friday,  Oct 24, 2014  8:25 AM ET by Maxim Group

Maxim Group rated Buy Sophiris Bio Inc. (NASDAQ: SPHS) on 10/24/2014, when the stock price was $2.97. Since
then, Sophiris Bio Inc. has lost 71.04% as of 09/16/2015's recent price of $0.86.
If you would have followed this Maxim Group's recommendation on SPHS, you would have lost 71.04% of your investment in 327 days.

Protox Therapeutics Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel receptor targeted therapeutic fusion proteins. The company develops its product based on its PORxin and INxin technology platforms. Its product candidates under clinical development include PRX302, a lead candidate from the PORxin platform, which is under a Phase IIa clinical trial for the treatment of localized and recurrent prostate cancer, as well as under a double-blinded placebo-controlled clinical trial for the treatment of benign prostatic hyperplasia; and PRX321, a lead candidate derived from INxin platform that has completed a Phase II clinical trial for the treatment of primary brain cancer and a Phase I clinical trial for renal cell and non-small cell lung cancers. The company also focuses on HUMxin technology platform, a program to develop chimeric and fully humanized fusion proteins based upon the Bcl-2 family of proteins. It has a collaborative research and clinical development agreement with BrainLAB AG for use of the BrainLAB proprietary drug delivery software iPlan Flow to plan treatments and catheter placement for delivery and distribution of PRX321. The company was founded in 2002 and is headquartered in Vancouver, Canada.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/24/2014 8:25 AM Buy
None
2.97 10.00
as of 8/27/2015
1 Week down  -4.44 %
1 Month down  -11.34 %
3 Months up  32.30 %
1 YTD down  -71.04 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy